個別化医療を目的とした5-fluorouracilの定量的治療効果予測システム構築に関する基礎的研究
Shinji Kobuchi · Institutional Repositories DataBase (IRDB) · date not stated
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Institutional Repositories DataBase (IRDB) · National Institute of Informatics · dissertation
Abstract
年 河 渕 真 治 目次 略語一覧……………………………………………………………………………………………………1 要約…………………………………………………………………………………………………………3 本論 第一章 1,2-dimethylhydrazine 誘発大腸癌モデルラットにおける 5-FU 体内動態及び肝臓中 dihydropyrimidine dehydrogenase 活性に関する検討 1-1.緒言…………………………………………………………………………………………6 1-2.材料および方法……………………………………………………………………………8 1-3.結果…………………………………………………………………………………………13 1-4.考察…………………………………………………………………………………………20 1-5.小括…………………………………………………………………………………………23 第二章 大腸癌化学療法における血漿中 dihydrouracil/uracil 比のバイオマーカーとしての 有用性 2-1.緒言…………………………………………………………………………………………24 2-2.材料および方法……………………………………………………………………………25 2-3.結果…………………………………………………………………………………………28 2-4.考察…………………………………………………………………………………………39 2-5.小括…………………………………………………………………………………………42 第三章 バイオマーカーを用いた PK-PD モデリングによる 5-FU 抗腫瘍効果予測システム 3-1.緒言…………………………………………………………………………………………43 3-2.材料および方法……………………………………………………………………………44 3-3.結果…………………………………………………………………………………………48 3-4.考察…………………………………………………………………………………………55 3-5.小括…………………………………………………………………………………………57 総括…………………………………………………………………………………………………………58 謝辞…………………………………………………………………………………………………………60 業績目録……………………………………………………………………………………………………61 引用文献……………………………………………………………………………………………………64 1 略語一覧 5-BU 5-bromouracil 5-FU 5-fluorouracil A 1 5-FU amounts in the central compartment A 2 5-FU amounts in the peripheral compartment ACF Aberrant crypt foci AIC Akaike's Information Criteria ALT alanine aminotransferase ANOVA analysis of variance AST aspartate aminotransferase AUC area under the concentration vs. time curve AUMC area under the first-moment curve to the last measured plasma concentration BSA bovine serum albumin C 1 5-FU concentration in the central compartment C 2 5-FU concentration in the peripheral compartment CL int intrinsic clearance CL tot total body clearance CRC colorectal cancer DHFU 5-fluoro-dihydrouracil DMH 1,2-dimethylhydrazine DPD dihydropyrimidine dehydrogenase EDTA ethylenediamine tetraacetic acid F h hepatic availability FP 5-fluorouracil and cisplatin chemotherapy i.v.intravenous k 1 first-order rate constant of transit k 12 rate constant of central compartment to peripheral compartment k 2 measure of drug potency k 21 rate constant of peripheral compartment to central compartment k e elimination rate constant LC-MS liquid chromatography-mass spectrometry LC-MS/MS liquid chromatography-tandem mass spectrometry LV leucovorin MRT mean resident time NADPH reduced form nicotinamide adenine dinucleotide phosphate NLR neutrophil to lymphocyte ratio PBPK model physiologically based pharmacokinetic model PD pharmacodynamics
Open the resolved locator · 10.34445/00000088
Metadata licence: OpenAlex metadata (CC0)